|Bid||57.39 x 100|
|Ask||57.65 x 100|
|Day's Range||56.65 - 57.80|
|52 Week Range||46.01 - 60.45|
|PE Ratio (TTM)||20.03|
|Dividend & Yield||1.56 (2.75%)|
|1y Target Est||N/A|
Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be?
Bristol-Myers Squibb Co NYSE:BMY
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.